<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <meta name="study:id" content="tirabrutinib-pcnsl-prospect-nayak">
    <meta name="study:title" content="PS1919 - Tirabrutinib for the treatment of relapsed or refractory primary central nervous system lymphoma: Efficacy and safety from the Phase II PROSPECT study">
    <meta name="study:fileName" content="Abstracts/TIRABRUTINIB-PCNSL-PROSPECT-NAYAK-PS1919.html">
    <meta name="study:cancerTypes" content="DLBCL,LBCL,B-NHL"> <meta name="study:lineOfTherapy" content="2L+">
    <meta name="study:evidenceType" content="Clinical trial">
    <meta name="study:drugs" content="Tirabrutinib,BTK inhibitor">

    <title>PS1919: Tirabrutinib in R/R PCNSL (PROSPECT Study) (Nayak/Grommes) - SOBI Themed</title>
    <script src="https://cdn.tailwindcss.com"></script>
    <script src="https://d3js.org/d3.v7.min.js"></script>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="abstract_styles.css"> </head>
<body class="abstract-page-body">
    <div class="slide-container">
        <div class="visual-abstract-container">
            <h2 class="visual-abstract-title">Visual Summary: PS1919 - Tirabrutinib in R/R Primary CNS Lymphoma (PROSPECT Study)</h2>
            <div class="visual-abstract-grid">
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-teal)"> <path d="M12 6.096c-1.058 0-2.02.468-2.704 1.248-.685.78-.996 1.788-.996 2.856s.311 2.076.996 2.856C9.98 13.84 10.942 14.31 12 14.31s2.02-.468 2.704-1.248.996-1.788.996 2.856-.311-2.076-.996-2.856C14.02 6.564 13.058 6.096 12 6.096zM12 12.81c-.53 0-1.008-.222-1.352-.588-.344-.366-.528-.852-.528-1.422s.184-1.056.528-1.422C10.992 9.012 11.47 8.79 12 8.79s1.008.222 1.352.588.528.852.528 1.422-.184-1.056-.528 1.422C13.008 12.588 12.53 12.81 12 12.81zm6.708 3.672A7.47 7.47 0 0012.024 15c-1.404 0-2.706.39-3.816 1.056A4.476 4.476 0 004.5 19.686V21h15v-1.314a4.476 4.476 0 00-3.792-3.624zM6.024 16.56c.84-.468 1.848-.768 2.904-.924A5.928 5.928 0 0112.024 15a5.928 5.928 0 013.096.636c1.056.156 2.064.456 2.904.924A2.988 2.988 0 0019.5 18.018V19.5h-15v-1.482a2.988 2.988 0 001.524-2.458zM4.5 7.032c0-1.068.312-2.076.996-2.856S7.2 3 8.256 3A7.47 7.47 0 0112.024 1.5c1.404 0 2.706.39 3.816 1.056A4.476 4.476 0 0119.5 6.186V7.5H4.5v-.468zM18 4.56c-.84.468-1.848.768-2.904-.924A5.928 5.928 0 0012.024 6a5.928 5.928 0 00-3.096.636 7.524 7.524 0 00-2.904.924A2.988 2.988 0 014.5 7.482V6H3V4.5A1.5 1.5 0 014.5 3h15A1.5 1.5 0 0121 4.5V6h-1.5v1.482a2.988 2.988 0 01-1.524 2.458L18 4.56z" />
                    </svg>
                    <h4>Population & Aim (N=48)</h4>
                    <p>Pts with R/R PCNSL. Aim: Evaluate efficacy (ORR) & safety of Tirabrutinib monotherapy in US pts (PROSPECT study).</p>
                </div>
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-teal)"> <path fill-rule="evenodd" d="M10.5 3.75a.75.75 0 01.75-.75h1.5a.75.75 0 01.75.75V4.5h3A2.25 2.25 0 0118.75 6.75v1.5a2.25 2.25 0 01-2.25 2.25H15.5V12h1.25a.75.75 0 010 1.5H15.5v1.5h.75a.75.75 0 010 1.5H15.5v1.5H18a.75.75 0 010 1.5h-2.5v1.5a.75.75 0 01-1.5 0V18h-1.5v1.5a.75.75 0 01-1.5 0V18h-1.5v1.5a.75.75 0 01-1.5 0v-3A2.25 2.25 0 016 14.25v-1.5A2.25 2.25 0 018.25 10.5H9.5V9H8.25A2.25 2.25 0 016 6.75v-1.5A2.25 2.25 0 018.25 3H10.5V3.75zm-1.5 6.75h6V6.75H9V10.5z" clip-rule="evenodd" />
                    </svg>
                    <h4>Intervention (Tirabrutinib Monotherapy)</h4>
                    <p>Oral Tirabrutinib 480mg QD until PD or unacceptable toxicity. Phase II, open-label.</p>
                </div>
                <div class="visual-abstract-item">
                     <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)"> <path fill-rule="evenodd" d="M3.75 3A.75.75 0 003 3.75v16.5a.75.75 0 00.75.75h16.5a.75.75 0 00.75-.75V3.75a.75.75 0 00-.75-.75H3.75zm14.25 1.5H6v13.5h12V4.5zm-10.5 3a.75.75 0 000 1.5h9a.75.75 0 000-1.5h-9zm0 3.75a.75.75 0 000 1.5h9a.75.75 0 000-1.5h-9zm0 3.75a.75.75 0 000 1.5H9a.75.75 0 000-1.5H6z" clip-rule="evenodd" />
                    </svg>
                    <h4>Key Efficacy (N=48, mF/U 11.2 mo)</h4>
                    <p>ORR: <span class="highlight-value">66.7%</span> (CR/CRu 43.8%, PR 22.9%). mDOR: 9.3 mo. mPFS: 6.0 mo. mOS: Not Reached.</p>
                </div>
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)"> <path fill-rule="evenodd" d="M12 2.25c-5.385 0-9.75 4.365-9.75 9.75s4.365 9.75 9.75 9.75 9.75-4.365 9.75-9.75S17.385 2.25 12 2.25zm-.092 14.444a.75.75 0 01-.092 0l-3.75-3.75a.75.75 0 111.06-1.06L12 14.813l3.182-3.182a.75.75 0 111.06 1.06l-3.75 3.75a.75.75 0 01-.53.22z" clip-rule="evenodd" />
                    </svg>
                    <h4>Safety & Conclusion</h4>
                    <p>Manageable. Any TRAE 75% (G≥3 27.1%). Supports tirabrutinib as potential option for R/R PCNSL.</p>
                </div>
            </div>
        </div>

        <div class="text-center mb-8">
            <h1 class="abstract-header-title">PS1919 - Tirabrutinib for the treatment of relapsed or refractory primary central nervous system lymphoma: Efficacy and safety from the Phase II PROSPECT study</h1>
            <p class="abstract-sub-header">Lakshmi Nayak, Christian Grommes, Avyakta Kallam, et al.</p>
            <p class="abstract-meta-info mt-2">EHA 2025 Congress | Abstract #PS1919 | Poster Presentation</p>
        </div>

        <div class="grid md:grid-cols-2 gap-x-8 gap-y-6">
            <div> <div class="abstract-card">
                    <h2 class="abstract-section-title">Background</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>Primary Central Nervous System Lymphoma (PCNSL) is a rare, aggressive non-Hodgkin lymphoma localized to the CNS.</li>
                        <li>Treatment options are limited, standard of care is not well established, and prognosis is poor, especially in the relapsed/refractory (r/r) setting.</li>
                        <li>Tirabrutinib, a highly potent, selective second-generation Bruton’s tyrosine kinase (BTK) inhibitor, is approved in Japan, Taiwan, and South Korea for r/r PCNSL based on a phase I/II study in Japanese patients.</li>
                        <li>Currently, no approved drug therapies exist for PCNSL in the US or Europe.</li>
                    </ul>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Aims</h2>
                    <p class="text-sm mb-1">To report the efficacy and safety results from the PROSPECT study (NCT04947319), an open-label, phase II study of tirabrutinib monotherapy in patients with r/r PCNSL conducted in the US.</p>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Methods & Study Design</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 mb-3 pl-2">
                        <li>Study Type: Open-label, phase II (PROSPECT study - NCT04947319).</li>
                        <li>Patient Population: Patients with r/r PCNSL.</li>
                        <li>Intervention: Oral tirabrutinib 480 mg monotherapy once daily (QD) until disease progression (PD) or unacceptable toxicity.</li>
                        <li>Primary Endpoint: Overall Response Rate (ORR) assessed by Independent Review Committee (IRC).</li>
                        <li>Secondary Endpoints: Duration of Response (DOR), Time To Response (TTR), Best Overall Response (BOR), safety.</li>
                        <li>Exploratory Endpoints: Overall Survival (OS), Progression-Free Survival (PFS).</li>
                        <li>Data Cutoff: November 1, 2024.</li>
                    </ul>
                     <div class="study-design-schema">
                        <h3 class="schema-title">PROSPECT Study: Tirabrutinib in R/R PCNSL</h3>
                        <div class="schema-enrollment">
                            <strong>Eligible Patients (N=48 Enrolled)</strong>
                            <span>Relapsed/Refractory PCNSL</span>
                            <span>(US Sites)</span>
                        </div>
                        <div class="schema-arrow-down">▼</div>
                        <div class="schema-phase-group">
                            <div class="schema-phase" style="flex-basis: 100%; background-color: var(--sobi-light-blue-bg); border-color: var(--sobi-dark-blue);">
                                <strong>Tirabrutinib Monotherapy</strong>
                                <span>480 mg PO QD</span>
                                <span>Until PD or unacceptable toxicity</span>
                            </div>
                        </div>
                        <div class="schema-arrow-down">▼</div>
                        <div class="schema-assessment-points">
                           <span>Primary EP: ORR (IRC)</span>
                           <span>Secondary EPs: DOR, TTR, BOR, Safety</span>
                           <span>Exploratory EPs: OS, PFS</span>
                        </div>
                    </div>
                </div>
            </div> <div> <div class="abstract-card">
                    <h2 class="abstract-section-title">Patient Characteristics (N=48)</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>Median Age: 65.5 years (range, 34-87).</li>
                        </ul>
                </div>
                <div class="abstract-card">
                    <h2 class="abstract-section-title">Efficacy Results (Median Follow-up: 11.2 months)</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li><strong>Overall Response Rate (ORR): 66.7% (32/48)</strong>
                            <ul class="list-circle list-inside ml-4">
                                <li>Complete Response Rate (CRR; CR + CRu): 43.8% (21/48)</li>
                                <li>Partial Response Rate (PRR): 22.9% (11/48)</li>
                            </ul>
                        </li>
                        <li>Median Duration of Response (mDOR): 9.3 months (range, 0.0-23.5).</li>
                        <li>Median Time To Response (mTTR): 0.95 months (range, 0.9-3.7).</li>
                        <li>Median Overall Survival (mOS): Not Reached (range, 1.0-33.0).</li>
                        <li>Median Progression-Free Survival (mPFS): 6.0 months (range, 0.0-26.0).</li>
                    </ul>
                    <div class="chart-container my-4">
                        <svg id="tirabrutinibResponseChart" width="350" height="280"></svg>
                        <div id="tirabrutinibResponseLegend" class="legend"></div>
                    </div>
                     <p class="text-sm mt-2">At data cutoff, 27.1% (n=13) of patients remained on tirabrutinib treatment.</p>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Safety Summary (N=48)</h2>
                     <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>Any-grade Treatment-Emergent Adverse Events (TEAEs): 97.9% (n=47).</li>
                        <li>Grade ≥3 TEAEs: 56.3% (n=27).</li>
                        <li>Any-grade Treatment-Related Adverse Events (TRAEs): 75.0% (n=36).
                            <ul class="list-circle list-inside ml-4">
                                <li>Most frequent TRAEs (any grade): Anemia (18.8%), Fatigue (14.6%), Neutrophil count decreased (14.6%), Pruritus (14.6%), Rash (14.6%), Maculo-papular rash (14.6%).</li>
                            </ul>
                        </li>
                        <li>Grade ≥3 TRAEs: 27.1% (n=13).
                             <ul class="list-circle list-inside ml-4">
                                <li>Most frequent G≥3 TRAEs: Neutrophil count decreased (8.3%), Rash maculo-papular (4.2%).</li>
                            </ul>
                        </li>
                        <li>Deaths related to TEAEs: 2 (4.2%) - seizure/pneumonia (n=1), fall (n=1); considered unrelated to study treatment.</li>
                        <li>Discontinuations due to AE: 1 patient (2.1%).</li>
                        <li>Main reasons for discontinuation: Disease progression (54.2%), death (8.3% - includes the 2 G5 TEAEs).</li>
                    </ul>
                </div>
            </div> </div> <div class="abstract-card mt-6">
            <h2 class="abstract-section-title">Summary & Conclusion</h2>
            <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                <li>Tirabrutinib monotherapy demonstrated an Overall Response Rate (ORR) of 66.7% and a Complete Response (CR/CRu) rate of 43.8% in patients with r/r PCNSL.</li>
                <li>The median Duration of Response (mDOR) was 9.3 months.</li>
                <li>The safety profile was manageable, with 27.1% of patients experiencing Grade ≥3 treatment-related adverse events.</li>
                <li>The PROSPECT trial results support tirabrutinib monotherapy as a potentially effective treatment option for patients with r/r PCNSL, a population with high unmet medical need.</li>
            </ul>
        </div>

        <div class="abstract-card mt-6 abbreviations-list">
            <h2 class="abstract-section-title">Abbreviations</h2>
            <p>AE, Adverse Event; BOR, Best Overall Response; BTKi, Bruton’s Tyrosine Kinase Inhibitor; CNS, Central Nervous System; CR, Complete Response; CRR, Complete Response Rate; CRu, Unconfirmed Complete Response; DOR, Duration of Response; EP, Endpoint; G, Grade; IRC, Independent Review Committee; mo, Months; mOS, Median Overall Survival; mPFS, Median Progression-Free Survival; mTTR, Median Time To Response; NHL, Non-Hodgkin Lymphoma; ORR, Overall Response Rate; OS, Overall Survival; PCNSL, Primary Central Nervous System Lymphoma; PD, Progressive Disease; PFS, Progression-Free Survival; PO, Per Os (by mouth); PRR, Partial Response Rate; Pts, Patients; QD, Once Daily; R/R, Relapsed or Refractory; TEAE, Treatment-Emergent Adverse Event; TRAE, Treatment-Related Adverse Event; TTR, Time To Response; US, United States; y, Years.</p>
        </div>

        <div class="abstract-card mt-6 reference-section">
            <h2 class="abstract-section-title">
                Reference
                <button id="copyReferenceBtn" class="copy-reference-button" title="Copy Reference">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor">
                        <path d="M7 3.5A1.5 1.5 0 018.5 2h3.879a1.5 1.5 0 011.06.44l3.122 3.121A1.5 1.5 0 0117 6.621V16.5a1.5 1.5 0 01-1.5 1.5h-7A1.5 1.5 0 017 16.5v-13z" />
                        <path d="M4.5 6A1.5 1.5 0 003 7.5v10A1.5 1.5 0 004.5 19h7a1.5 1.5 0 001.5-1.5v-2.5a.75.75 0 00-1.5 0v2.5a.5.5 0 01-.5.5h-7a.5.5 0 01-.5-.5v-10a.5.5 0 01.5-.5h2.5a.75.75 0 000-1.5H4.5z" />
                    </svg>
                    Copy
                </button>
            </h2>
            <p id="referenceSectionContent">Nayak L, Grommes C, Kallam A, et al. Tirabrutinib for the treatment of relapsed or refractory primary central nervous system lymphoma: Efficacy and safety from the Phase II PROSPECT study. Abstract #PS1919 presented at European Haematology Association (EHA) June 12–15, 2025, Milan, Italy.</p>
        </div>

        <div class="abstract-footer-info">
            <p>EHA 2025 Congress | Abstract #PS1919 | Abstract Release: 05/22/2025 | Presentation: 06/14/2025</p>
            <p class="text-xs italic mt-1">© 2025 American Society of Clinical Oncology, Inc. Reused with permission. This abstract was accepted and previously presented at the 2025 ASCO Annual Meeting. All rights reserved.</p>
            <p>For Research & Informational Purposes Only.</p>
        </div>
    </div> <script defer src="abstract_features.js"></script>
    <script>
        function drawTirabrutinibResponseChart(containerId, legendContainerId) {
            const chartTitle = "Response Rates with Tirabrutinib (N=48)";
            const chartData = [
                { response: "ORR", rate: 66.7, color: "var(--sobi-teal-darker)" }, // Using a distinct color for ORR
                { response: "CRR (CR+CRu)", rate: 43.8, color: "var(--sobi-teal)" },
                { response: "PRR", rate: 22.9, color: "var(--sobi-light-teal-bg)" }
            ];

            const svg = d3.select(containerId);
            const legendContainer = d3.select(legendContainerId);
            svg.selectAll("*").remove();
            legendContainer.selectAll("*").remove();

            let containerWidth = 350;
            const chartWrapper = svg.node() ? svg.node().closest('.chart-container') : null;
            if (chartWrapper) {
                containerWidth = Math.max(chartWrapper.getBoundingClientRect().width * 0.90, 280);
            }
            
            const svgWidth = containerWidth;
            const svgHeight = +svg.attr("height");
            const margin = { top: 50, right: 20, bottom: 50, left: 50 };
            const chartWidth = svgWidth - margin.left - margin.right;
            const chartHeight = svgHeight - margin.top - margin.bottom;

            if (chartWidth <= 0 || chartHeight <=0) return;

            const g = svg.append("g").attr("transform", `translate(${margin.left},${margin.top})`);

            const xScale = d3.scaleBand()
                .domain(chartData.map(d => d.response))
                .range([0, chartWidth])
                .padding(0.3);

            const yScale = d3.scaleLinear()
                .domain([0, 100]) // Percentage
                .range([chartHeight, 0]);

            g.append("g")
                .attr("transform", `translate(0,${chartHeight})`)
                .call(d3.axisBottom(xScale))
                .selectAll("text")
                .attr("class", "axis-text")
                .style("font-size", "10px")
                .attr("transform", "translate(0,5)");

            g.append("g")
                .call(d3.axisLeft(yScale).ticks(5).tickFormat(d => d + "%"))
                .selectAll("text")
                .attr("class", "axis-text")
                .style("font-size", "10px");
            
            g.append("text")
                .attr("transform", "rotate(-90)")
                .attr("y", 0 - margin.left + 10)
                .attr("x", 0 - (chartHeight / 2))
                .attr("dy", "1em")
                .style("text-anchor", "middle")
                .attr("class", "axis-label")
                .text("Response Rate (%)");

            g.append("g").attr("class", "grid")
                .call(d3.axisLeft(yScale).ticks(5).tickSize(-chartWidth).tickFormat(""))
                .selectAll("line").style("stroke", "var(--sobi-light-gray)").style("stroke-opacity", "0.7");

            g.selectAll(".bar")
                .data(chartData)
                .enter().append("rect")
                .attr("class", "bar")
                .attr("x", d => xScale(d.response))
                .attr("y", d => yScale(d.rate))
                .attr("width", xScale.bandwidth())
                .attr("height", d => chartHeight - yScale(d.rate))
                .attr("fill", d => d.color)
                .attr("rx", 3).attr("ry", 3);

            g.selectAll(".bar-label")
                .data(chartData)
                .enter().append("text")
                .attr("class", "chart-label")
                .attr("x", d => xScale(d.response) + xScale.bandwidth() / 2)
                .attr("y", d => yScale(d.rate) - 5)
                .attr("text-anchor", "middle")
                .style("font-size", "10px")
                .style("fill", "var(--sobi-dark-text)")
                .text(d => `${d.rate.toFixed(1)}%`);
            
            svg.append("text")
                .attr("x", svgWidth / 2)
                .attr("y", margin.top / 2)
                .attr("text-anchor", "middle")
                .style("font-size", "13px")
                .style("font-weight", "600")
                .style("fill", "var(--sobi-dark-blue)")
                .text(chartTitle);

            const legendItems = legendContainer.selectAll(".legend-item")
                .data(chartData).enter().append("div").attr("class", "legend-item");
            legendItems.append("div").attr("class", "legend-color-box").style("background-color", d => d.color);
            legendItems.append("span").text(d => d.response);
        }
        
        function debounce(func, wait) {
            let timeout;
            return function executedFunction(...args) {
                const later = () => { clearTimeout(timeout); func(...args); };
                clearTimeout(timeout);
                timeout = setTimeout(later, wait);
            };
        };

        const debouncedDrawTiraResponseChart = debounce(() => drawTirabrutinibResponseChart("#tirabrutinibResponseChart", "#tirabrutinibResponseLegend"), 250);
        
        window.addEventListener('resize', debouncedDrawTiraResponseChart);
        document.addEventListener('DOMContentLoaded', debouncedDrawTiraResponseChart);
        if (document.readyState === "complete" || document.readyState === "interactive") {
             setTimeout(debouncedDrawTiraResponseChart, 0); 
        }
    </script>
</body>
</html>
